The Bank actively participating in the restructuring of our credit system and after participating in tender process launched by the Bank of Greece and the EFSF, absorbs sound portion of the bank PROBANK AE
A healthy portion of PROBANK, based on data March 31, 2013, which will be absorbed by the National Bank concerns:
• € 3.103 million in assets, of which € 2.597 million Loans
• € 3.203 million in liabilities, of which € 3.123 million Deposits
• Network 112 stores throughout Greece
The offer of the National Bank fully guarantee depositors and customers of PROBANK, whose transactions will be carried out properly and without any change to ensure the smooth operation of the bank.
The absorption of the assets will be accompanied with appropriate capitalization of the EFSF and next time, independent auditing firm will evaluate the Balance Sheet of PROBANK. If a dispute arises between the temporarily apotimitheisas value of assets and liabilities and final value as derived from the evaluation will be covered by the EFSF, in accordance with the applicable procedure, and will have the effect of providing additional liquidity.
The National Bank welcomed the officers and employees of PROBANK within the Group recognizes the efforts made under adverse conditions to keep the bank at a high level and looks forward to their active participation to meet the challenges set by the Group in the future .
Clearwire Chairman resigning, article on GOOG taking over Sprint, Gold man racing the price targets, $ 5 and $ 6 Call options for Jan. Looks like it is going to be all good news for Sprint.
Any idea if Google buys sprint, what will be the price/share they will pay.
DryShips Raised To Buy From Hold By Lazard Capital >DRYS
Oct 13, 2009 07:35:10 (ET)
(END) Dow Jones Newswires
October 13, 2009 07:35 ET (11:35 GMT)
In my opinion they will let the option expire worthless and release the data after Sep Options expire. Any other thoughts ?
Sep options 7.5 and 10 call options will fall in next two weeks......
Food for thought ?
Just before the release of a phase 3 trails of a major product for the company. Reason, results are not as per his and medical communities expectation.
8k tells there is no disagreement . Yes, that is true but what it does not tell you is that he may be disappointed by the phase 3 trails and the general direction of the company. At his age aperson of his repute do not want to be wasting time with a company with little future.........
Just a thought. For all you know I may be wrong. just trying to see if someone really knows why he quit now.
Please do not buy or sell based on my post> Do your own research
I rate it 50-50. Reason I am not knowledgable enough on the subject . But I would be interested in someone who knows this better to weigh in and share their thoughts. I am expecting some doctors that know this to jump in. Not interested in the thoughts of stock junkies
Following points may lead to a phase 3 clinical trial failure. anyone more knowledgeable please shed more light on these points :
1. Primary outcome analysis used the Unified PD Rating Scale (UPDRS) parts II (activities of daily living) and III (motor examination). Further secondary assessments included Scale for the Assessment of Positive Symptoms (SAPS), Clinical Global Impression Scale-severity (CGI-S), and the Parkinson's Psychosis Rating Scale (PPRS).
2. For the safety analysis, 72.4% and 77.4% of patients, respectively, reported adverse events (AEs), although the 4 serious AEs reported were all considered not related to the study drug. With pimavanserin, the most common AEs were somnolence, oedema, and blood urea increase, while placebo AEs were hallucinations, dizziness, fall, headache, confusion, and hypotension.
Williams noted that based on these data, 39 of these patients have since entered an ongoing open-label, safety extension study. After 48 months in this extension study, pimavanserin remains well tolerated at doses up to 60 mg daily.
He just lost $7700 in 1 minute and tommorrow will loose another $15400 by close . Not bad lossing $ 23,100 in 2 days. take some lessons in trading